Literature DB >> 20179283

Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.

Alan E Jones1, Nathan I Shapiro, Stephen Trzeciak, Ryan C Arnold, Heather A Claremont, Jeffrey A Kline.   

Abstract

CONTEXT: Goal-directed resuscitation for severe sepsis and septic shock has been reported to reduce mortality when applied in the emergency department.
OBJECTIVE: To test the hypothesis of noninferiority between lactate clearance and central venous oxygen saturation (ScvO2) as goals of early sepsis resuscitation. DESIGN, SETTING, AND PATIENTS: Multicenter randomized, noninferiority trial involving patients with severe sepsis and evidence of hypoperfusion or septic shock who were admitted to the emergency department from January 2007 to January 2009 at 1 of 3 participating US urban hospitals.
INTERVENTIONS: We randomly assigned patients to 1 of 2 resuscitation protocols. The ScvO2 group was resuscitated to normalize central venous pressure, mean arterial pressure, and ScvO2 of at least 70%; and the lactate clearance group was resuscitated to normalize central venous pressure, mean arterial pressure, and lactate clearance of at least 10%. The study protocol was continued until all goals were achieved or for up to 6 hours. Clinicians who subsequently assumed the care of the patients were blinded to the treatment assignment. MAIN OUTCOME MEASURE: The primary outcome was absolute in-hospital mortality rate; the noninferiority threshold was set at Delta equal to -10%.
RESULTS: Of the 300 patients enrolled, 150 were assigned to each group and patients were well matched by demographic, comorbidities, and physiological features. There were no differences in treatments administered during the initial 72 hours of hospitalization. Thirty-four patients (23%) in the ScvO2 group died while in the hospital (95% confidence interval [CI], 17%-30%) compared with 25 (17%; 95% CI, 11%-24%) in the lactate clearance group. This observed difference between mortality rates did not reach the predefined -10% threshold (intent-to-treat analysis: 95% CI for the 6% difference, -3% to 15%). There were no differences in treatment-related adverse events between the groups.
CONCLUSION: Among patients with septic shock who were treated to normalize central venous and mean arterial pressure, additional management to normalize lactate clearance compared with management to normalize ScvO2 did not result in significantly different in-hospital mortality. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00372502.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179283      PMCID: PMC2918907          DOI: 10.1001/jama.2010.158

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  28 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

Review 2.  Bench to bedside: the role of mitochondrial medicine in the pathogenesis and treatment of cellular injury.

Authors:  John A Watts; Jeffrey A Kline
Journal:  Acad Emerg Med       Date:  2003-09       Impact factor: 3.451

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Use of goal-directed therapy for severe sepsis and septic shock in academic emergency departments.

Authors:  Alan E Jones; Jeffrey A Kline
Journal:  Crit Care Med       Date:  2005-08       Impact factor: 7.598

5.  Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis.

Authors:  Ryan C Arnold; Nathan I Shapiro; Alan E Jones; Christa Schorr; Jennifer Pope; Elisabeth Casner; Joseph E Parrillo; R Phillip Dellinger; Stephen Trzeciak
Journal:  Shock       Date:  2009-07       Impact factor: 3.454

6.  Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule.

Authors:  Nathan I Shapiro; Richard E Wolfe; Richard B Moore; Eric Smith; Elizabeth Burdick; David W Bates
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

7.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

Review 8.  Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update.

Authors:  Steven M Hollenberg; Tom S Ahrens; Djillali Annane; Mark E Astiz; Donald B Chalfin; Joseph F Dasta; Stephen O Heard; Claude Martin; Lena M Napolitano; Gregory M Susla; Richard Totaro; Jean-Louis Vincent; Sergio Zanotti-Cavazzoni
Journal:  Crit Care Med       Date:  2004-09       Impact factor: 7.598

9.  Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock).

Authors:  M H Weil; A A Afifi
Journal:  Circulation       Date:  1970-06       Impact factor: 29.690

10.  Early lactate clearance is associated with improved outcome in severe sepsis and septic shock.

Authors:  H Bryant Nguyen; Emanuel P Rivers; Bernhard P Knoblich; Gordon Jacobsen; Alexandria Muzzin; Julie A Ressler; Michael C Tomlanovich
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

View more
  296 in total

1.  [Prognostic value of difference between peripheral venous and arterial partial pressure of carbon dioxide in patients with septic shock: a pilot study].

Authors:  Wei Gao; Yong Zhang; Haibin Ni; Jialiu Zhang; Dandan Zhou; Liping Yin; Feng Zhang; Hao Chen; Beibei Zhang; Wei Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Hospital-based acute care use in survivors of septic shock.

Authors:  Alexandra Ortego; David F Gaieski; Barry D Fuchs; Tiffanie Jones; Scott D Halpern; Dylan S Small; S Cham Sante; Byron Drumheller; Jason D Christie; Mark E Mikkelsen
Journal:  Crit Care Med       Date:  2015-04       Impact factor: 7.598

3.  Counterpoint: should lactate clearance be substituted for central venous oxygen saturation as goals of early severe sepsis and septic shock therapy? No.

Authors:  Emanuel P Rivers; Ronald Elkin; Chad M Cannon
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

4.  Point: should lactate clearance be substituted for central venous oxygen saturation as goals of early severe sepsis and septic shock therapy? Yes.

Authors:  Alan E Jones
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

5.  [Therapy concepts for septic diseases].

Authors:  R Wildenauer; C T Germer
Journal:  Chirurg       Date:  2010-05       Impact factor: 0.955

6.  What's new with biomarker-driven clinical strategy in sepsis and circulatory failure?

Authors:  Armand Mekontso Dessap; Lorraine B Ware; Lila Bouadma
Journal:  Intensive Care Med       Date:  2015-09-21       Impact factor: 17.440

7.  Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan.

Authors:  Francis Pike; Donald M Yealy; John A Kellum; David T Huang; Amber E Barnato; Tammy L Eaton; Derek C Angus; Lisa A Weissfeld
Journal:  Crit Care Resusc       Date:  2013-12       Impact factor: 2.159

8.  Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health.

Authors:  Charles R Evans; Alla Karnovsky; Melissa A Kovach; Theodore J Standiford; Charles F Burant; Kathleen A Stringer
Journal:  J Proteome Res       Date:  2013-12-09       Impact factor: 4.466

9.  Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.

Authors:  Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer
Journal:  Ann Am Thorac Soc       Date:  2015-01

10.  Repeat lactate level predicts mortality better than rate of clearance.

Authors:  Zachary D W Dezman; Angela C Comer; Gordon S Smith; Peter F Hu; Colin F Mackenzie; Thomas M Scalea; Jon Mark Hirshon
Journal:  Am J Emerg Med       Date:  2018-03-07       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.